Contribution of Val/Ile87 residue in the extracellular domain in agonist-induced current responses of the human and rat P2X7 receptors

Emily A Caseley 1,2 · Stephen P Muench 2 · Lin-Hua Jiang 2

Abstract
The P2X7 receptor (P2X7R) is an ATP-gated cation channel with a critical role in many physiological and pathological processes, and shows prominent functional differences across mammalian species, exemplified by larger current responses of the rat (r) P2X7R to ATP and its analogue BzATP and a greater sensitivity to agonists compared with the human (h) P2X7R. Here, we showed that substitution of Val87 residue in the extracellular domain of the hP2X7R with isoleucine in the rP2X7R increased the current responses of the hP2X7R to both ATP and BzATP. Conversely, introduction of reciprocal I87V mutation in the rP2X7R led to a noticeable but statistically insignificant reduction in the current responses of the rP2X7R to ATP and BzATP. The mutations did not affect the sensitivity of the human and rat P2X7Rs to ATP and BzATP. These results suggest a contribution of Val/Ile87 in agonist-induced current responses of human and rat P2X7Rs, which helps to better understand the molecular determinants for species-dependent function of the mammalian P2X7Rs.

Keywords P2X7 receptor · Species difference · Agonist-induced currents · Whole-cell recording

Introduction
P2X receptors (P2XRs) comprise a group of seven trimeric, nonselective cation channels that are selectively activated by extracellular ATP [1]. The mammalian P2X7 receptor (P2X7R) is a key mediator of responses induced by high levels of ATP associated with tissue inflammation and damage, hypoxia, and emotional stress, and plays a critical role in diverse pathologies such as inflammatory disorders, neurodegenerative diseases, mood disorders, and cancers [2–6]. The P2X7Rs of different species exhibit striking differences in functional properties; it has been well documented that the agonist concentrations evoking half of the maximal response (EC50) for ATP and its analogue BzATP are several-fold higher at the human (h) P2X7R than at the rat (r) P2X7R and, additionally, agonist-evoked responses from the hP2X7R are smaller than those from the rP2X7R [7–10]. Previous studies identified two residues, one at position 155 in the extracellular domain and the other at 348 in the second transmembrane domain, as important determinants for the difference in agonist-induced current responses between human and rat P2X7Rs [11, 12]. In this short communication, we report residue at position 87 in the extracellular domain that contributes the current responses of the human and rat P2X7Rs to ATP and BzATP.

Methods
Homology modelling and ligand docking The structures of the rP2X7R in the closed and ATP-bound open states (Protein Data Bank code 6U9V and 6U9W, respectively) were used to produce the structural models of the hP2X7R. Modeller version 9.12 [13] was used to produce these models, which were analysed using MolProbity [14] as detailed in our previous studies [15, 16]. AutoDock version 4.2 [17] was used...
to dock ATP and BzATP to a cavity file consisting of a 15-Å sphere surrounding the P2X7R ATP-binding site and affinity grid files were generated using the auxiliary program AutoGrid.

**Site-directed mutagenesis** The cDNA for wild-type (WT) human or rat P2X7 receptor subunit with an EE epitope in the C-terminus was subcloned in pcDNA3.1 vector and used in our previous studies [11, 15]. Point mutations were introduced using a PCR-based protocol we previously described [18] (for more details, see supplemental information) and confirmed by commercial sequencing (Beckman Coulter Genomics).

**Expression of P2X7R and patch-clamp recording** WT and mutant P2X7Rs were transiently expressed in human embryonic kidney (HEK) 293 cells, and agonist-induced whole-cell currents were recorded using patch-clamp technique, as previously described [11, 15]. The EC50 values were derived by fitting the concentration-response relationship curves to the Hill equation [14]. Further details are presented in supplemental information. Agonist-induced currents recorded in parallel experiments were used for comparisons.

**Data analysis** All results, where appropriate, are presented as the mean ± standard error of the mean (SEM).

Statistical analysis was carried out using Student’s t test for two groups or one-way analysis of variance test and Tukey’s post hoc test for more than two groups, with the difference considered to be significant at p < 0.05.

**Results**

**Effects of mutating residues in the extracellular domain in hP2X7R on BzATP-induced currents**

Sequence analysis of the extracellular domain of the human (and monkey) versus the rat (and mouse) P2X7Rs [7, 19, 20] identified 25 residues of interest (Fig. 1S). We chose a subset of 13 residues and substituted each of them in the hP2X7R with that in the rP2X7R, expressed the mutant hP2X7Rs in HEK293 cells in parallel with the WT human and rat P2X7Rs, and assessed the mutational effects on the current responses to 300 μM BzATP, a maximal concentration (Fig. 1a, b). As anticipated, BzATP elicited much smaller currents from WT-hP2X7R than WT rP2X7R (Fig. 1b). Seven mutations had no effect on, and five mutations reduced, BzATP-induced currents (Fig. 1b). V87I was the only mutation increasing BzATP-induced currents, with the mean amplitude significantly higher than that from WT hP2X7R and comparable that from WT rP2X7R (Fig. 1b). Val/Ile87 is located in the top part of the extracellular domain of the receptors (Fig. 1c, d).

**Effects of reciprocally mutating residues at position 87 in human and rat P2X7Rs on agonist-evoked currents**

To better understand the contribution of Val87 in the hP2X7R and Ile87 in the rP2X7R in species difference, we next examined the effect of V87I mutation on the hP2X7R and the effect of reciprocal mutation I87V on the rP2X7R in their current responses to a range of BzATP concentrations (Fig. 2a, b). BzATP at all concentrations elicited larger currents from hP2X7R-V87I than WT hP2X7R (top two panels in Fig. 2a). The mean maximal current amplitude from hP2X7R-V87I was significantly larger than that from WT hP2X7R (Fig. 2b). Conversely, BzATP at all concentrations evoked smaller currents from rP2X7R-I87V relative to WT rP2X7R (bottom two panels in Fig. 2a). The mean maximal current amplitude from rP2X7R-I87V was smaller than that from WT rP2X7R, but the difference did not reach statistical significance (Fig. 2b). We also examined the effects of both mutations on the current responses of human and rat P2X7Rs to a range of ATP concentrations (Fig. 2c, d). Similarly, ATP at all concentrations evoked larger currents from hP2X7R-V87I than from WT hP2X7R, with the maximal current amplitude from hP2X7R-V87I significantly larger than that from WT hP2X7R (Fig. 2c, d). Introduction of the I87V mutation in the rP2X7R decreased the current responses to ATP at all concentrations. The maximal current amplitude from rP2X7R-I87V was smaller than that from WT rP2X7R and again the reduction was not statistically significant (Fig. 2d). Collectively, these results indicate that reciprocal mutation of the residue at position 87 interchanged the current responses of the human and rat P2X7Rs to both BzATP and ATP, albeit with the human-to-rat mutation resulting in more prominent or significant effects.

It is known that the hP2X7R is less sensitive to agonists than the rP2X7R [7–11]. We further examined the effects of reciprocally mutating the residue at position 87 on the sensitivity of human and rat P2X7Rs to BzATP and ATP by determining the EC50 values. The BzATP EC50 for WT hP2X7R was approximately 5-fold greater than that for WT rP2X7R (Fig. 2e) and the ATP EC50 for WT hP2X7R was 3-folder higher than that for WT rP2X7R (Fig. 2f). The BzATP EC50 for hP2X7R-V87I was similar to that for WT hP2X7R, and the BzATP EC50 for rP2X7R-I87V was close to that for WT P2X7R (Fig. 2e). Similarly, the ATP EC50 for both hP2X7R-V87I and rP2X7R-I87V showed no difference to that for respective WT receptors (Fig. 2f). These results indicate no effect of the mutations on the sensitivity of the human and rat P2X7Rs to both BzATP and ATP.
Discussion

The mammalian P2X7Rs are well known for their striking inter-species functional differences, as shown by the agonist-induced current responses and agonist sensitivity [7, 10, 11]. To gain a better understanding of the molecular determinants for such species difference between the human and rat P2X7Rs, we selected 13 residues in the extracellular domains and examined the effects of substituting individual residue in the hP2X7R with that in the rP2X7R as indicated. All the mutations, except for V87I, led to either no change or a reduction in BzATP-induced current response. Here, we did not further examine these mutants and how these mutations induced loss of function mechanistically remains unclear. V87I increased BzATP-induced hP2X7R-mediated currents, with the current amplitude close to that from WT rP2X7R (Fig. 1b). We further examined this gain-of-function mutation in the hP2X7R and the reciprocal I87V mutation in the rP2X7R in terms of their effects on the agonist-induced current amplitude and the agonist sensitivity at the human and rat P2X7Rs. We confirmed the reported differences in the current amplitude and the sensitivity to BzATP and ATP between human and rat P2X7Rs (Fig. 2a–d). Importantly, our results showed that the current responses from V87I-hP2X7R to both BzATP (Fig. 2a, b) and ATP (Fig. 2c, d) were consistently higher than those from WT-hP2X7R. Conversely, introduction of the I87V mutation in the rP2X7R reduced the current responses to both BzATP (Fig. 2a, b) and ATP (Fig. 2c, d), though the differences were statistically insignificant. Moreover, our results showed no effect of V87I in the hP2X7R or I87V in the rP2X7R on the EC50 values for ATP and BzATP (Fig. 2e, f). Collectively, these results suggest that Val/Ile87 residue mainly influences the difference in agonist-induced current responses between human and rat P2X7Rs.

The recently determined rP2X7R structure [21] provides useful information to understand or rule out the mechanisms by which Val/Ile87 residue contributes to the mutational effects on human and rat P2X7Rs. This residue is positioned distant to the agonist-binding site in the human, rat, and mouse P2X7Rs (Fig. 1c, d and Fig. S2A) [22], and thus, the mutations are unlikely to influence agonist binding, which is consistent with no effect on the sensitivity to ATP or BzATP (Fig. 2e, f). As we previously showed, Ala/Thr348 in the second transmembrane domain lining the ion-conducting pore contributes to the difference in the current responses of human and rat P2X7Rs [11]. Immunofluorescent imaging
revealed no noticeable mutational effect on the expression and subcellular distribution of human and rat P2X7Rs (Fig. S3). The location of Val/Ile87 is at the top of the ‘head’ region of the P2X7Rs, with Val87 in the hP2X7R in the vicinity of residues including Glu186 [23] and Gln187 [24] (Fig. S2B), mutation of which were shown to affect hP2X7R activation, prompting us to hypothesise that Val/Ile87 may impact the closure of the ATP-binding vestibule that induces the conformational changes essential for channel opening [25]. Further investigations are required to examine this hypothesis. Residues flanking Val87 in the hP2X7R were reported to participate in allosteric binding of AZ10606120, a human and rat P2X7R antagonist [26]. It would be interesting to examine whether Val/Ile87 contributes to the action of antagonists exhibiting species differences.

In summary, this study reports contribution of extracellular Val/Ile87 residue in agonist-induced current responses of human and rat P2X7Rs, which helps us better understand the molecular determinants for species difference in the function of the mammalian P2X7Rs.

Authors’ contributions Conceptualization (L-HJ); generation of mutations (HJB, EAC); electrophysiology, immunofluorescent imaging, and data analysis (EAC); data interpretation (EAC, L-HJ); manuscript writing and revision (EAC); supervision and manuscript revision (L-HJ, SPM).

Funding information This research was supported by the Wellcome Trust (099758/Z/12/Z) and BBSRC (BB/C517317/1).

Compliance with ethical standards

Conflict of interest The authors that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013–1067
2. Di Virgilio F, Sarti AC, Grassi F (2018) Modulation of innate and adaptive immunity by P2X ion channels. Curr Opin Immunol 52:51–59
3. Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14:1–18
4. Jiang LH, Roger S (2020) Targeting the P2X7 receptor in microglial cells to prevent brain inflammation. Neural Regen Res 15:1245–1246
5. Roger S, Jelassi B, Couillin I, Pelegrin P, Besson P, Jiang L-H (2015) Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives. Biochim Biophys Acta 1848:2584–2602
6. Bartlett R, Stokes L, Shytre R (2014) The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev 66:638–675
7. Rassendren F, Buell GN, Virgilio C, Collo G, North RA, Surprenant A (1997) The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272:5482–5486
8. Michel A, Clay W, Ng S, Roman S, Thompson K, Condreay J, Hall M, Holbrook J, Livermore D, Senger S (2008) Identification of regions of the P2X7 receptor that contribute to human and rat species differences in antagonist effects. Br J Pharmacol 155:738–751
9. Michel AD, Ng SW, Roman S, Clay WC, Dean DK, Walter DS (2009) Mechanism of action of species-selective P2X7 receptor antagonists. Br J Pharmacol 156:1312–1325
10. Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157:1203–1214
11. Bradley HJ, Baldwin JM, Goli GR, Johnson B, Zou J, Sivaprasad Rao A, Baldwin SA, Jiang L-H (2011) Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem 286:8176–8187
12. Stokes L, Fuller SJ, Shytre R, Skarratt KK, Gu BJ, Wiley JS (2010) Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J 24:2916–2927
13. Webb B, Sali A (2016) Comparative protein structure modeling using MODELLER. Curr Protoc Bioinformatics 54:5.6.1–5.6.37
14. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB III, Snieckus J, Richardson JS (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35:W375–W383
15. Casey EA, Muench SP, Fishwick CW, Jiang L-H (2016) Structure-based identification and characterisation of structurally novel human P2X7 receptor antagonists. Biochem Pharmacol 116:130–139
16. Casey EA, Muench SP, Baldwin SA, Simmons K, Fishwick CW, Jiang L-H (2015) Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in
response between rat and human. Bioorg Med Chem Lett 25:3164–3167
17. Yang W, Jiang L-H (2013) Site-directed mutagenesis to study the structure–function relationships of ion channels. In: Ion Channels. Springer, Berlin, pp 257–266
18. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791
19. Bradley HJ, Browne LE, Yang W, Jiang LH (2011) Pharmacological properties of the rhesus macaque monkey P2X7 receptor. Br J Pharmacol 164:743–754
20. Jiang LH, Baldwin JM, Roger S, Baldwin SA (2013) Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol 4:55
21. McCarthy AE, Yoshioka C, Mansoor SE (2019) Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization. Cell 179:659–670
22. Pasqualetto G, Brancale A, Young MT (2018) The molecular determinants of small-molecule ligand binding at P2X receptors. Front Pharmacol 9:58
23. Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Suprenant A, Jiang L-H (2010) Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44:347–355
24. Chong JH, Zheng G-G, Ma YY, Zhang HY, Nie K, Lin YM, Wu KF (2010) The hyposensitive N187D P2X7 mutant promotes malignant progression in nude mice. J Biol Chem 285:36179–36187
25. Hattori M, Gouaux E (2012) Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature 485:207–212
26. Allsopp RC, Dayl S, Schmid R, Evans RJ (2017) Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120. Sci Rep 7:725

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.